Medincell at fresh record high FDA expands indication for schizophrenia treatment

Medincell SA

13/10/2025 09:18

** Shares in French pharmaceutical company Medincell MEDCL.PA rise around 14% to hit a new all-time high after the U.S. Food and Drug Administration (FDA) approved the use of Uzedy, a schizophrenia treatment co-developed with Teva, to treat patients with bipolar disorder indication

** "This development is expected to boost sales momentum and, in turn, drive royalty income and commercial milestone payments for Medincell," Midcap Partners analysts say

** Portzamparc notes the approval says a lot about BEPO's potential, Medicell's technology platform used to develop the treatment

** If gains hold, Medincell shares will see their best day since April 2024; stock hit new intraday record high of 31.4 euros

(Reporting by Mathias de Rozario in Gdansk)

((mathias.derozario@thomsonreuters.com;))